LGVN Longeveron Inc

Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced that the Company will release its second quarter 2022 financial results on Friday, August 12, 2022 before the open of the U.S. financial markets. Management will host a conference call to discuss the Company’s financial results and provide a corporate update on the same day at 8:30 a.m. EST.

Dial-in NumberU.S. Dial-in Number: 844-200-6205Canada Dial-in Number: 833-950-0062All Other Locations Dial-in Number: 929-526-1599Access code: 788626

U.S. Replay Dial-in Number: 866-813-9403Canada Replay Dial-in Number: 226-828-7578All Other Locations Dial-in Number: 44-204-525-0658Conference ID: 924827

An audio webcast of the call may also be accessed from the ‘Investors’ page of the Longeveron website at www.longeveron.com. A replay of the call will be available on the Longeveron website shortly after completion of the call.

About Longeveron Inc.

Longeveron is a clinical stage biotechnology company developing cellular therapies for specific aging-related and life-threatening conditions. The Company’s lead investigational product is the Lomecel-B™ cell-based therapy product, which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young, healthy adult donors. Longeveron believes that by using the same cells that promote tissue repair, organ maintenance, and immune system function, it can develop safe and effective therapies for some of the most difficult disorders associated with the aging process and other medical disorders. Longeveron is currently sponsoring Phase 1 and 2 clinical trials in the following indications: Alzheimer’s Disease, hypoplastic left heart syndrome (HLHS), Aging Frailty, and Acute Respiratory Distress Syndrome (ARDS). Additional information about the Company is available at www.longeveron.com.

Investor Contact:

Elsie YauStern IR, Inc.212-698-8700 elsie.yau@sternir.com

Media:

Neil HareGVC Strategies (202) 550-0297neil@gvcstrategies.com